Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Rezolute ( (RZLT) ).
On July 15, 2025, Rezolute, Inc. announced the completion of enrollment for its Phase 3 sunRIZE clinical study, which investigates the efficacy and safety of ersodetug in treating congenital hyperinsulinism (cHI). The study, involving 63 participants, aims to address the significant unmet medical need in managing hypoglycemia in cHI patients, as current standard of care therapies have proven inadequate. Preliminary data from the study highlights the severe disease burden and frequent hypoglycemia events experienced by participants, underscoring the potential impact of ersodetug as a novel treatment option. The study’s pivotal portion is expected to conclude by the end of 2025, with topline results anticipated to provide insights into the therapeutic benefits of ersodetug for this rare condition.
The most recent analyst rating on (RZLT) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Rezolute stock, see the RZLT Stock Forecast page.
Spark’s Take on RZLT Stock
According to Spark, TipRanks’ AI Analyst, RZLT is a Neutral.
Rezolute’s overall stock score is impacted by its challenging financial performance, with persistent losses and operational inefficiencies. However, technical analysis shows moderate upward momentum, and positive corporate events, including significant funding and promising clinical trial progress, offer potential upside. Valuation remains weak with negative earnings, suggesting cautious optimism for the stock’s future.
To see Spark’s full report on RZLT stock, click here.
More about Rezolute
Rezolute, Inc. operates in the biopharmaceutical industry, focusing on developing therapies for rare and metabolic diseases. The company is primarily engaged in the research and development of treatments for conditions such as congenital hyperinsulinism, with its lead product candidate being ersodetug, a monoclonal antibody targeting insulin receptors.
Average Trading Volume: 1,363,344
Technical Sentiment Signal: Buy
Current Market Cap: $464.5M
For an in-depth examination of RZLT stock, go to TipRanks’ Overview page.